Literature DB >> 18779440

Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.

Pál Pacher1, Partha Mukhopadhyay, Rajesh Mohanraj, Grzegorz Godlewski, Sándor Bátkai, George Kunos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18779440      PMCID： PMC2568884          DOI： 10.1161/HYPERTENSIONAHA.105.063651

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  72 in total

1.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

2.  Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

Authors:  Sabine Steffens; Niels R Veillard; Claire Arnaud; Graziano Pelli; Fabienne Burger; Christian Staub; Meliha Karsak; Andreas Zimmer; Jean-Louis Frossard; François Mach
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

3.  The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.

Authors:  José Antonio López-Moreno; Gustavo González-Cuevas; Miguel Navarro
Journal:  Neurobiol Dis       Date:  2006-10-24       Impact factor: 5.996

4.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Authors:  Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 6.  Evidence for novel cannabinoid receptors.

Authors:  Malcolm Begg; Pál Pacher; Sándor Bátkai; Douglas Osei-Hyiaman; László Offertáler; Fong Ming Mo; Jie Liu; George Kunos
Journal:  Pharmacol Ther       Date:  2005-01-11       Impact factor: 12.310

7.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

8.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

Authors:  Daniela Cota; Giovanni Marsicano; Matthias Tschöp; Yvonne Grübler; Cornelia Flachskamm; Mirjam Schubert; Dorothee Auer; Alexander Yassouridis; Christa Thöne-Reineke; Sylvia Ortmann; Federica Tomassoni; Cristina Cervino; Enzo Nisoli; Astrid C E Linthorst; Renato Pasquali; Beat Lutz; Günter K Stalla; Uberto Pagotto
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.

Authors:  Luis M Ruilope; Jean-Pierre Després; André Scheen; Xavier Pi-Sunyer; Guiseppe Mancia; Alberto Zanchetti; Luc Van Gaal
Journal:  J Hypertens       Date:  2008-02       Impact factor: 4.844

10.  Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.

Authors:  Won-il Jeong; Douglas Osei-Hyiaman; Ogyi Park; Jie Liu; Sándor Bátkai; Partha Mukhopadhyay; Norio Horiguchi; Judith Harvey-White; Giovanni Marsicano; Beat Lutz; Bin Gao; George Kunos
Journal:  Cell Metab       Date:  2008-03       Impact factor: 27.287
View more
  42 in total

1.  Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury.

Authors:  Partha Mukhopadhyay; Bėla Horváth; Mohanraj Rajesh; Shingo Matsumoto; Keita Saito; Sándor Bátkai; Vivek Patel; Galin Tanchian; Rachel Y Gao; Benjamin F Cravatt; György Haskó; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2010-11-09       Impact factor: 7.376

Review 2.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 3.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

Review 4.  Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Authors:  Cyrus DeSouza; Vivian Fonseca
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 5.  Endocannabinoids and cardiac contractile function: pathophysiological implications.

Authors:  Sándor Bátkai; Pál Pacher
Journal:  Pharmacol Res       Date:  2009-08       Impact factor: 7.658

6.  Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report.

Authors:  Masayuki Nogi; David Fergusson; John Michael Chua Chiaco
Journal:  Hawaii J Med Public Health       Date:  2014-04

7.  Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats.

Authors:  Anna Pędzińska-Betiuk; Jolanta Weresa; Marek Toczek; Marta Baranowska-Kuczko; Irena Kasacka; Ewa Harasim-Symbor; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

8.  Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; György Haskó; Pál Pacher
Journal:  Biochem Biophys Res Commun       Date:  2008-11-06       Impact factor: 3.575

Review 9.  The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.

Authors:  Tamás Bíró; Balázs I Tóth; György Haskó; Ralf Paus; Pál Pacher
Journal:  Trends Pharmacol Sci       Date:  2009-07-14       Impact factor: 14.819

Review 10.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.